Skip to main content

PBC

1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
OCAPhase 32 trials
Active Trials
NCT05706129Recruiting270Est. Mar 2029
NCT06715319Completed100Est. Apr 2024
Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
1 program
LUM001PHASE_21 trial
Active Trials
NCT01904058Completed66Est. Apr 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
BiocorpOCA
Mirum PharmaceuticalsLUM001
BiocorpOCA

Clinical Trials (3)

Total enrollment: 436 patients across 3 trials

NCT06715319BiocorpOCA

Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis

Start: Oct 2021Est. completion: Apr 2024100 patients
Phase 3Completed
NCT01904058Mirum PharmaceuticalsLUM001

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Start: Aug 2013Est. completion: Apr 201566 patients
Phase 2Completed
NCT05706129BiocorpOCA

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Start: Mar 2023Est. completion: Mar 2029270 patients
Phase 1/2Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 436 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.